Shareholders Approve 3 Million Share Increase for Equity Incentive Plan
NKTR has more than doubled off its 52-week low of $7.99.
Summary
Nektar Therapeutics shareholders approved a 3 million share increase for the equity incentive plan, creating a potential dilution of nearly 9% of outstanding shares.
Key Events · Financing and Capital Events · NKTR
-
Share Incentive Plan Expansion Approved
Shareholders authorized an additional 3,000,000 shares for the 2017 Performance Incentive Plan.
-
Potential Dilution
If all 3,000,000 newly authorized shares were issued, dilution would be approximately 8.88% of current outstanding shares.
-
Director Re-elected
Howard W. Robin was re-elected to the Board of Directors until the 2029 Annual Meeting.
-
Auditor Ratified
Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
Analysis · NKTR · Life Sciences
Shareholders approved an increase of 3,000,000 shares for the company's performance incentive plan. This authorization creates a significant overhang, representing a potential dilution of approximately 8.88% of current outstanding shares. While intended for employee compensation, this future issuance will dilute existing shareholder value.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1615 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NKTR was trading at $57.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $7.99 to $109.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.